Composition and release form:
Melbek tablets 7.5 mg.
The package contains 10 (5, 30) tablets. Melbek forte tablets 15 mg. There are 10 tablets in a package.
Melbek injection solution 1.5 ml. There are 10 ampoules in a package.
Melbek rectal suppositories 15 mg. There are 10 suppositories in a package.
1 tablet of Melbek contains: 7.5 mg (15 mg) of meloxicam. Excipients: Aerosil 200, povidone K30, lactose, magnesium stearate, crospovidone, sodium citrate, Avicel RN 102.
1 ampoule of Melbek contains: 15 mg of meloxicam. Excipients: glycofurol, meglumine, poloxamer 188, sodium chloride, glycine, water for injection, 1 m HCl or 1 m NaOH.
Mode of application:
Melbek is prescribed orally, intramuscularly and rectally. The dosage of Melbek should be selected individually. It is recommended to use the drug in the lowest effective dosages for the shortest period of time.
Melbek in the form of tablets is taken during meals, without chewing, once a day, 7.5-15 mg. It is recommended to use Melbek intramuscularly only during the first few days of therapy, subsequently switching to oral forms of the drug.
When combined with the drug using tablets and solution for intramuscular administration, the total daily dosage should not exceed 15 mg. Melbek in the form of suppositories is administered at 15 mg (1 suppository) per day. The maximum dosage of the drug is 15 mg per day, for patients with severe renal failure, as well as patients on hemodialysis, the maximum daily dosage is 7.5 mg.
With a moderate or slight decrease in kidney function, with liver cirrhosis in the compensated stage, no dosage adjustment is required. For patients with an increased risk of side effects, an initial dose of 7.5 mg/day is recommended. Melbek in solution form is not suitable for intravenous administration.
Side effects:
When using the drug Melbek, the following may develop:
- nausea, vomiting, constipation, diarrhea, abdominal pain, flatulence, belching, esophagitis, gastroduodenal ulcers, hepatitis, colitis, gastritis, transient increases in bilirubin or transaminases; - anemia, changes in blood count (leukopenia, thrombocytopenia, cytopenia); - skin irritation, itching, urticaria, stomatitis; - dizziness, tinnitus, headache, mood changes, lethargy; - swelling, hot flashes, increased blood pressure, palpitations; - increased levels of urea, creatinine, acute renal failure; - visual impairment, conjunctivitis; - hypersensitivity reaction, angioedema.
Note!
The description of the drug Melbek on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use. Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug).
Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
Interaction with other drugs:
The simultaneous use of two or more drugs from the NSAID group increases the ulcerogenic risk and the risk of gastrointestinal bleeding due to the synergistic effect of the drugs. It is not recommended to combine Melbek with lithium salts, since NSAIDs can reduce the excretion of lithium by the kidneys, which may cause its accumulation and contribute to its toxicity. When taken simultaneously, Melbek can increase the toxic effect of methotrexate on hematopoiesis, which requires constant monitoring of the dynamics of hemogram parameters. When taken simultaneously, Melbek enhances the effect of heparin and ticlopidine, resulting in an increased risk of gastrointestinal bleeding.
Melbek may reduce the contraceptive effect of the intrauterine device. When taking Melbek concomitantly with diuretics, patients should consume sufficient amounts of fluid. Meloxicam can reduce the effectiveness of antihypertensive drugs (ACE inhibitors, β-adrenergic receptor blockers). NSAIDs, ACE inhibitors and angiotensin II receptor antagonists have a synergistic effect on glomerular filtration, which can lead to the development of acute renal failure in patients with a history of impaired renal function. Meloxicam may bind to cholestyramine in the digestive tract, which will accelerate the elimination of meloxicam.
Melbek should not be combined with cyclosporine to avoid increasing the risk of nephrotoxicity of cyclosporine. The pharmacokinetic interaction of Melbek with digoxin, antacids and furosemide when taken simultaneously has not been established. It is possible that Melbek may interact with oral antidiabetic drugs.
